The competitive nature of type II photosensitizers in the transfer of excitation energy for the generation of singlet oxygen (O) presents significant challenges in the design of type I photosensitizers to produce the superoxide anion radical (O). In this study, we present an efficient method for the direct transformation of type II photosensitizers into type I photosensitizers through the implementation of an artificial light-harvesting system (ALHSs) involving a two-step sequential energy transfer process. The designed supramolecular complex (DNPY-SBE-β-CD) not only has the ability to generate O as type II photosensitizers, but also demonstrates remarkable fluorescence properties in aqueous solution, which renders it an efficient energy donor for the development of type I photosensitizers ALHSs, thereby enabling the efficient generation of O. Meanwhile, to ascertain the capability and practicality of this method, two organic reactions were conducted, namely the photooxidation reaction of thioanisole and oxidative hydroxylation of arylboronic acids, both of which display a high level of efficiency and exhibit significant catalytic performance. This work provides an efficient method for turning type II photosensitizers into type I photosensitizers by a two-step sequential energy transfer procedure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829035PMC
http://dx.doi.org/10.1039/d3sc05820dDOI Listing

Publication Analysis

Top Keywords

type photosensitizers
32
two-step sequential
12
sequential energy
12
energy transfer
12
singlet oxygen
8
transfer process
8
type
8
photosensitizers
8
efficient method
8
photosensitizers type
8

Similar Publications

Ferroptosis: A novel cell death modality in or synergistic therapeutic strategy for photodynamic therapy.

Photodiagnosis Photodyn Ther

December 2024

Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China. Electronic address:

Although there has been significant progress in current comprehensive anticancer treatments centered on surgery, postoperative recurrence and tumor metastasis still significantly affect both prognosis and quality of life of the patient. Hence, the development of precisely targeted tumor therapies and exploration of immunotherapy represent ideal strategies for tumor treatment. Photodynamic therapy (PDT) is a localized and relatively safe treatment modality that not only induces multiple modes of tumor cell death but also mediates the secondary immunological responses against tumor resistance and metastasis.

View Article and Find Full Text PDF

X-ray-induced photodynamic therapy (X-PDT) represents a promising new method of cancer treatment. A novel type of nanoscintillator based on cerium fluoride (CeF) nanoparticles (NPs) modified with flavin mononucleotide (FMN) has been proposed. A method for synthesizing CeF-FMN NPs has been developed, enabling the production of colloidal, spherical NPs with an approximate diameter of 100 nm, low polydispersity, and a high fluorescence quantum yield of 0.

View Article and Find Full Text PDF

An NIR-II Two-Photon Excitable AIE Photosensitizer for Precise and Efficient Treatment of Orthotopic Small-Size Glioblastoma.

Adv Mater

December 2024

School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong (CUHK-Shenzhen), Shenzhen, Guangdong, 518172, P. R. China.

The existence of residual small-size tumors after surgery is a major factor contributing to the high recurrence rate of glioblastoma (GBM). Conventional adjuvant therapeutics involving both chemotherapy and radiotherapy usually exhibit unsatisfactory efficacy and severe side effects. Recently, two-photon photodynamic therapy (TP-PDT), especially excited by the second near-infrared (NIR-II) light, offers an unprecedented opportunity to address this challenge, attributed to its combinational merits of PDT and TP excitation.

View Article and Find Full Text PDF

Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages for treating hypoxic tumor. However, most of the reported type-I PSs have a contingency of molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy transfer (EET) process. Therefore, it is urgent to understand molecular design mechanisms for type-I PSs.

View Article and Find Full Text PDF

Two case reports of MDA5-type seronegative dermatomyositis.

SAGE Open Med Case Rep

December 2024

Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Dermatomyositis (DM) is an autoimmune idiopathic inflammatory myopathy with characteristic dermatologic manifestations. Myositis-specific autoantibodies (MSAs) delineate DM subtypes and their prognoses. Uncommonly, patients present with distinct clinical features of DM, including photosensitive dermatitis, heliotrope rash, Gottron's papules, and nailfold changes; however, their autoimmune serology is negative for expected MSAs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!